FDA reviewers question proposed study design for Salix's Xifaxan in IBS
This article was originally published in Scrip
Executive Summary
Shares of Salix Pharmaceuticals tumbled as low as 11.3% on 14 November, or $4.24, after US drug reviewers questioned whether a new trial design for the firm's antibiotic Xifaxan (rifaximin) would gauge whether the drug is effective and safe in treating patients with irritable bowel syndrome with diarrhea (IBS-D).